Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) was the target of unusually large options trading on Thursday. Stock investors bought 37,582 call options on the stock. This is an increase of approximately 4,688% compared to the average daily volume of 785 call options.
Analysts Set New Price Targets
ROIV has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, June 18th. Cantor Fitzgerald upgraded Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th.
Read Our Latest Research Report on ROIV
Insider Transactions at Roivant Sciences
Institutional Trading of Roivant Sciences
A number of institutional investors and hedge funds have recently made changes to their positions in ROIV. Parallel Advisors LLC lifted its position in shares of Roivant Sciences by 80.5% in the first quarter. Parallel Advisors LLC now owns 2,485 shares of the company’s stock worth $25,000 after buying an additional 1,108 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after buying an additional 1,948 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Roivant Sciences in the fourth quarter worth about $39,000. UMB Bank n.a. lifted its position in shares of Roivant Sciences by 112.7% in the first quarter. UMB Bank n.a. now owns 4,143 shares of the company’s stock worth $42,000 after buying an additional 2,195 shares during the last quarter. Finally, Fifth Third Bancorp lifted its position in shares of Roivant Sciences by 59.3% in the first quarter. Fifth Third Bancorp now owns 5,118 shares of the company’s stock worth $52,000 after buying an additional 1,905 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.
Roivant Sciences Trading Down 1.8%
Shares of NASDAQ:ROIV opened at $11.39 on Friday. Roivant Sciences has a 1 year low of $8.73 and a 1 year high of $13.06. The business has a fifty day simple moving average of $11.11 and a 200 day simple moving average of $10.92. The firm has a market cap of $7.74 billion, a price-to-earnings ratio of -45.56 and a beta of 1.16.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last announced its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.15). Roivant Sciences had a negative return on equity of 14.76% and a negative net margin of 225.71%. The company had revenue of $7.57 million during the quarter, compared to analyst estimates of $62.17 million. During the same period in the prior year, the firm earned ($0.23) EPS. On average, sell-side analysts forecast that Roivant Sciences will post -0.92 EPS for the current year.
Roivant Sciences Company Profile
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
- Five stocks we like better than Roivant Sciences
- Buy P&G Now, Before It Sets A New All-Time High
- EA Just Caught a Monster Upgrade: Bullish Breakout Ahead?
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Stocks Hitting All-Time Highs With More Room to Run
- What is a Bond Market Holiday? How to Invest and Trade
- QuantumScape Soars 30%: What Drove the Next-Gen EV Stock’s Rally
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.